Prognostic prediction of BRAFV600E and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas

Clinical Laboratory

Volumn 58, Issue 9-10, 2012, Pages 919-926

  Gao, Wei Li ^a,b   Wie, Liu Li ^a   Chao, Ye Guo ^a   Wie, Lu ^a   Song, Teng Li ^b  

^a HUZHOU CENTRAL HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

BRAFV600E mutation; Classic variant of PTCs; Follicular variant of PTCs; Papillary thyroid carcinomas (PTCs); Sodium iodide symporter (NIS) functional expression

Indexed keywords

B RAF KINASE; GENOMIC DNA; IODINE 131; LEVOTHYROXINE; PROTEIN BRAF V600E; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROTROPIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CORRELATION ANALYSIS; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; ULTRASOUND; WHOLE BODY SCINTISCANNING;

ADULT; CARCINOMA; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IODINE RADIOISOTOPES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RADIOTHERAPY, ADJUVANT; SYMPORTERS; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 84868560636     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.111217     Document Type: Article

References (31)

1. Braverman LE, Utiger DL. In: Werner and Ingbar's The Thyroid: a fundamental and clinical text. 8th edn. Lippincott, Williams & Wilkins: Philadelphia, USA 2000.
2. Schlumberger M, Pacini F. Prognostic factors. In: Thyroid Tumors, Nucléon, Paris 2003:111-25.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
4. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9. (Pubitemid 39361432)
5. Xing M. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clin Endocrinol 2005;63:263-6. (Pubitemid 41233442)
6. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455-64. (Pubitemid 43886668)
7. Lupi C, Giannini R, Ugolini C, Projetti A, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-90. (Pubitemid 350074715)
8. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-20. (Pubitemid 38619884)
9. Trovisco V, Soares P, Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006;37:781-6. (Pubitemid 43902956)
10. Dohán O, Baloch Z, Bánrévi Z, et al. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 2001;86:2697-700. (Pubitemid 32545725)
11. Wapnir IL, van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003;88:1880-8. (Pubitemid 36623418)
12. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006;13:257-69.
13. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;92:2840-3. (Pubitemid 47037399)
14. Namba H, Nakashima M, Hayashi T Maeda S, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7. (Pubitemid 37153748)
15. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404. (Pubitemid 37452745)
16. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9. (Pubitemid 41759286)
17. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010;321:86-93.
18. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62. (Pubitemid 40896444)
19. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-71.
20. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006;30:216-22. (Pubitemid 43740191)
21. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumor aggressiveness. Virchows Arch 2005;446:589-95. (Pubitemid 40922263)
22. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. J Clin Endcrinol 2006;65:364-8.
23. Michels JJ, Jacques M, Henry-Amar M, et al. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007;38:212-9. (Pubitemid 46096555)
24. Liu D, Hu S, Hou P, et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007;13:1341-9. (Pubitemid 46424076)
25. Mitsutake N, Knauf JA, Mitsutake S, et al. Conditional BRAFV 600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465-73. (Pubitemid 40490159)
26. Romei C, Ciampi R, Faviana P, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Enodocr Related Cancer 2008;15:511-20. (Pubitemid 351880839)
27. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;927:2840-3. (Pubitemid 47037399)
28. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011;10:385-94.
29. Saito T, Endo T, Kawaguchi A, et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 1998;101:1296-300. (Pubitemid 28166826)
30. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006;13:797-826. (Pubitemid 44763258)
31. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)